PDCD1 and glioblastoma: PD-L1 expression was positively correlated with CMTM6 expression in CHOL, GBM, HNSC, SARC, and STAD, implying that high CMTM6 expression could respond favorably to anti-PD-1/PD-L1 immunotherapy in these tumor types.